b-patch buprenorphine 5 microgram/hour transdermal drug delivery system pouches
au pharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene terephthalate; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.
b-patch buprenorphine 10 microgram/hour transdermal drug delivery system pouches
au pharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; levulinic acid; oleyl oleate; povidone; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.
b-patch buprenorphine 20 microgram/hour transdermal drug delivery system pouches
au pharma pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; polyethylene terephthalate; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; glycidyl methacrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate; butyl acrylate; acrylic acid; aluminium acetylacetonate; heptane - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.
so-cee 500mg capsule
atc healthcare international corp.; distributor: atc healthcare international corporation - ascorbic acid - capsule - 500mg
carbomux 500mg hard gelatin capsule
atc healthcare international corp; distributor: atc healthcare international corp - carbocisteine - hard gelatin capsule - 500mg
vita d-max 1000 iu soft gelatin capsule
atc healthcare international corporation; distributor: atc healthcare international corporation - colecalciferol - soft gelatin capsule - 1000 iu
vita-e 400 iu softgel capsule
atc healthcare international corp.; distributor: atc healthcare international corp. - d-alpha tocopherol (vitamin e) - softgel capsule - 400 iu
azalan 200 mg/ 325 mg capsule
atc healthcare international corp.; distributor: atc healthcare international corporation - ibuprofen , paracetamol - capsule - 200 mg/ 325 mg
none 20mg delayed-release capsule
ambica international corporation; distributor: atc healthcare international corp. - omeprazole - delayed-release capsule - 20mg
redoxfatout 120 mg capsule
atc healthcare international corp. - orlistat - capsule - 120 mg